anti-CD19/CD3 T-cell engaging bispecific antibody CLN-978

{
  "id": "MLC-T-ONC-010280",
  "term": "anti-CD19/CD3 T-cell engaging bispecific antibody CLN-978",
  "field": "Oncology and biomedicine",
  "definition": "A half-life extended T-cell engaging bispecific antibody comprised of a single chain variable fragment (scFv) targeting the tumor-associated antigen (TAA) CD19, a scFv targeting the T-cell surface antigen CD3, and a single-domain heavy chain variable domain (VHH)-based antibody specific for human serum albumin (HSA), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 T-cell engaging bispecific antibody CLN-978 targets and binds to both CD19 antigen expressed on tumor cells and CD3 antigen expressed on T cells. This results in the cross-linking of T cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. The HSA binding domain prolongs the half-life of CLN-978.",
  "synonyms": [
    "anti-CD19/anti-CD3 T-cell engaging bispecific antibody CLN-978",
    "CD19xCD3 T-cell engager CLN-978"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd19-cd3-t-cell-engaging-bispecific-antibody-cln-978/"
}